Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

EClinicalMedicine(2022)10.1016/j.eclinm.2022.101323Source: DataRank Database

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial is a research paper published in EClinicalMedicine (2022). On theSindex it has a DataRank of 1.3. It has been cited 55 times, with 32 citing works in its 1-hop citation network.

N/A

1.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access55 citations · 32 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04764422

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 4.93)OA: goldTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 47%Citation Network 53%

Base Score Contribution

0.604

From this paper's citation signal

Citation Network Contribution

0.691

From 25 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 32 citers.

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
iScience202320 citations31 referencesContributes 0.098
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
Proceedings of the National Academy of Sciences202256 citations46 referencesContributes 0.088
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial
Vaccine20243 citations21 referencesContributes 0.066
The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate
PLoS ONE202211 citations51 referencesContributes 0.049
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
EBioMedicine202396 citations95 referencesContributes 0.048

Authors (47)

Viravarn Luvira ORCID,Saranath Lawpoolsri ORCID,Sant Muangnoicharoen ORCID,Supitcha Kamolratanakul,Chaisith Sivakorn ORCID

Live enrichment

PubMed:35284808 PMC:PMC8903824 OpenAlex:https://openalex.org/W4221052099

Pfizer

Grant: P01 AI097092–07

Pfizer

Grant: R01 AI145870–03

National Institutes of Health

Grant: 75N93019C00051

National Institutes of Health

Grant: 75N93021C00014

National Institutes of Health

Grant: HHSN272201400008C

National Institutes of Health

Grant: INV-021239

National Cancer Institute

Grant: 1P30 CA 196521–01

JPB Foundation

Grant: 2020–215,611

NCI NIH HHS

Grant: P30 CA196521

NIAID NIH HHS

Grant: R01 AI145870

NIAID NIH HHS

Grant: P01 AI097092

National Institutes of Health

Grant: 1P30CA196521-01

Mouse Genetics

National Institutes of Health

Grant: 3R01AI145870-02S1

Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection

National Institutes of Health

Grant: 5P01AI097092-04

Monoclonal Antibody Technology Core

Icahn School of Medicine at Mount Sinai

School of Medicine, CHA University

Bill and Melinda Gates Foundation

AstraZeneca

National Research Council

FWCI

4.93

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.eclinm.2022.101323

publisherhttps://doi.org/10.1016/j.eclinm.2022.101323

publisherhttps://api.elsevier.com/content/article/PII:S2589537022000530?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589537022000530?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35284808

Fields of Study

SARS-CoV-2 and COVID-19 ResearchVirology and Viral DiseasesRespiratory viral infections research0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

MedicinePlaceboInterim analysisAdverse effectmyalgiaImmunogenicityVaccinationInternal medicineRandomized controlled trialVirologyImmunologyAntibodyPathologyMedicine (General)Alternative medicineEpidemiologySocial SciencesCoronavirus Disease 2019 ResearchFOS: Health sciencesR5-920Paramyxovirus Infections and EpidemiologyHealth SciencesVaccinesFOS: Clinical medicineArticlesInfectious DiseasesHealthFactors Affecting Vaccine Hesitancy and Acceptance

Sustainable Development Goals

SDG 0: No poverty